Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Erbitux (Cetuximab)

Drug (Brand/Generic)

Erbitux (cetuximab, C225)

Company/Licensee

ImClone Systems Inc/ Bristol-Myers Squibb/ Merck-Serono

Therapy Class

Anti-neoplastic agent

Product Description

Anti-EGFR MAb

Current Indication

Metastatic colorectal cancer, locally advanced squamous cell carcinoma of the head and neck

Market Sector

Oncology

Development Status

Approved
Expand

Go Top